eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2022
vol. 8
 
Share:
Send email
Share:
abstract:
Original paper

Therapeutic efficacy of dendritic cell injection in advanced hepatocellular carcinoma: the role of natural killer and T lymphocytes

Amr Zaghloul
1
,
Khalid Rashad
2
,
Hala Gabr
3
,
Ahmed Nabil
2
,
Adel Abdel-Moneim
2

  1. Tropical Medicine and Gastroenterology, Sohag Faculty of Medicine, Egypt
  2. Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt
  3. Department of Clinical Pathology, Faculty of Medicine, Cairo University, Egypt
Clin Exp HEPATOL 2022; 8, 2: 153-160
DOI: https://doi.org/10.5114/ceh.2022.116999
Online publish date: 2022/06/20
View full text Get citation
 
PlumX metrics:
Aim of the study
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related fatalities worldwide. The burden of HCC incidence in Egypt has doubled in the last 10 years. The primary aim of this research was to assess the safety and efficacy of autologous dendritic cells (DCs) generated from peripheral blood.

Material and methods
This trial was carried out at the Sohag Center of Cardiac and Digestive System. Patients with HCC were grouped into two groups (control group and DC injection group). The study group received intradermal autologous DCs twice weekly for three weeks, with a total of six vaccinations of 0.7 IU, whereas the control group received conservative treatment.

Results
The study group showed statistically significant clinical improvement in the Child-Pugh score and overall survival. Laboratory evaluation revealed a significant reduction of a-fetoprotein, from 232 ng/dl at baseline to 193 ng/dl after 3 months to 153 ng/dl after 6 months, in the injection group, as compared with the control group, which increased from 228 ng/dl at baseline to 269 ng/dl at 3 months to 305 ng/dl at 6 months. Also, liver function improved significantly at both 3 and 6 months in the injected group compared with the control group. Regarding lymphocyte subsets, T-cytotoxic lymphocytes (CD8+) and natural killer cells (CD56+ve) increased significantly in the injection group.

Conclusions
DC injection may be effective treatment of patients with advanced HCC to improve quality of life.

keywords:

hepatocellular carcinoma, dendritic cell vaccine, natural killer cells
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.